Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Astra Values Entrepreneurial Spirit, Keeps R&D “Armies” Away From CAT

  • News

Executive Summary

AstraZeneca seeks to preserve the entrepreneurial spirit of its acquisitions by giving them the opportunity to operate differently. "Our strategy is ... to bring them into the AstraZeneca family, but make sure they've got the opportunity to operate differently," CEO David Brennan said during AstraZeneca's fourth quarter earnings call Feb. 1

You may also be interested in...



AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas

AstraZeneca's focus on improving manufacturing efficiencies, on the heels of similar moves by Merck and Pfizer, may signal that manufacturing is the next target for industry cost-cutting initiatives

Big Pharma More Comfortable Giving Acquired Firms Independence

Big pharma appears increasingly comfortable giving acquired companies operational independence

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By